Hanmi Pharmaceutical and Ferring Pharmaceuticals Korea Sign Joint Sales Agreement for Nocturia Treatments

Supply of Minirin and Nocdurna Begins at Clinics and Hospitals

Hanmi Pharmaceutical and Ferring Pharmaceuticals Korea announced on January 12 that they had signed a joint sales agreement on January 7 for "Minirin Tablets" and "Minirin Melt Sublingual Tablets" (active ingredient: desmopressin acetate, Minirin), treatments for nocturia and enuresis, as well as "Nocdurna Sublingual Tablets" (active ingredient: desmopressin acetate, Nocdurna), a treatment for nocturia.

Jae-Hyun Park, CEO of Hanmi Pharmaceutical (right), and Minjung Kim, CEO of Ferring Pharmaceuticals Korea, are taking a commemorative photo after signing a joint sales agreement at the Hanmi Pharmaceutical headquarters in Songpa-gu, Seoul, on the 7th. Hanmi Pharmaceutical

Under this agreement, Hanmi Pharmaceutical will be solely responsible for the domestic supply and distribution of Minirin and Nocdurna. In terms of sales and marketing, Ferring Pharmaceuticals Korea will focus on general hospitals, while Hanmi Pharmaceutical will be responsible for clinics and hospitals.

Minirin contains desmopressin, a synthetic analogue based on the antidiuretic hormone vasopressin, and improves nocturia symptoms by reducing nighttime urine volume through its antidiuretic action. It is widely used as the standard treatment for primary nocturnal enuresis in children aged five and older. It is also effective in treating nocturia symptoms associated with "nocturnal polyuria," which accounts for about 88% of adult nocturia cases and involves excessive nighttime urine production.

Nocdurna is a low-dose formulation of Minirin developed to treat nocturia symptoms in adults. It is designed to reduce the risk of hyponatremia, a concern especially among elderly patients aged 65 and older. In addition, as a sublingual tablet, it offers improved convenience and bioavailability.

Jae-Hyun Park, CEO of Hanmi Pharmaceutical, stated, "We are very pleased that this partnership with Ferring Pharmaceuticals Korea will allow us to reliably supply clinically proven treatments for nocturia symptoms to patients in Korea. Based on Hanmi Pharmaceutical's extensive sales and marketing capabilities and on-the-ground expertise, we will strengthen close collaboration with healthcare professionals and do our utmost to ensure that more patients can benefit from the therapeutic value of Minirin and Nocdurna."